课题基金 / 基金详情

Does exenatide in conjunction with therapeutic hypothermia reduce cerebral palsy in neonatal hypoxic-ischemic encephalopathy?

Does exenatide in conjunction with therapeutic hypothermia reduce cerebral palsy in neonatal hypoxic-ischemic encephalopathy?
艾塞那肽联合低温治疗能否减少新生儿缺氧缺血性脑病的脑瘫?
批准号:
MR/X004724/1
负责人:
Suresh Victor
金额:
$184.02万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2023
资助国家:
英国
项目状态:
未结题
起止时间:
2023 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
缺氧缺血性脑病(HIE)发生在婴儿出生时,血液流量和向大脑输送的氧气减少。当供应给大脑的血液和氧气减少时,婴儿有时可能会对大脑造成伤害。并不是所有暴露在这种情况下的新生儿都会受到脑损伤。然而,如果发生脑损伤,死亡或神经残疾的风险很高,包括脑瘫、学习困难、癫痫和视力障碍。HIE是一个全球性问题,每年导致40万婴儿出现破坏性的神经发育障碍,占全球疾病总负担的2.4%。该小组以前曾成功地开发出治疗HIE的治疗性低温(降温)疗法。为婴儿降温3天可降低HIE后脑损伤的风险。然而,降温疗法只能帮助大约七分之一的HIE婴儿。因此,需要进一步的治疗来进一步改善HIE后的脑功能和脑恢复。此外,临床试验表明,降温在低收入和中等收入国家并不有效。我们现在提出,埃塞那肽与降温治疗相结合,将降低出生时HIE婴儿脑性瘫痪的发生率。埃克塞那肽是一种获得许可的抗糖尿病药物,现在可以作为仿制药使用。众所周知,它作用于大脑中存在的受体,以保护它免受进一步的伤害。在帕金森病方面,动物研究和早期人类研究的结果令人鼓舞,导致了目前正在进行的大型III期临床试验。我们利用新生儿缺氧缺血性脑病(HIE)啮齿动物模型研究了艾塞那肽的脑保护作用。我们知道,如果艾塞那肽分四次注射,间隔12小时,在经历了脑血流和氧气输送减少的啮齿类动物中,脑损伤会显著减少。我们还知道,我们可以在受伤后等待长达6个小时才开始治疗,这对需要前往另一家医院接受治疗的婴儿很有帮助。在这项提议中,我们希望在更高的动物模型(仔猪)上重复实验。我们将首先确定对仔猪进行脑保护所需的艾塞那肽的最佳剂量。然后,我们将随机选择那些暴露在缺乏血液和氧气供应的小猪接受或不接受埃克塞那肽治疗,并找出两组之间的大脑是否存在差异。埃克塞那肽目前以笔的形式在商业上出售,允许成年人皮下注射。当给婴儿皮下给药时,他们的吸收可能是缓慢和不稳定的。由于我们想要可靠地在体内迅速获得高浓度的埃克塞那肽,我们希望将埃塞那肽作为静脉输液进行管理。为了做到这一点,并确保该药物对新生儿安全,我们的目标是开发一种新的静脉注射埃塞那肽配方。埃克塞那肽已在高剂量动物研究和人类过量病例报告中被证明是安全的。然而,由于我们是第一次给婴儿使用埃塞那肽,我们希望确保它不会导致新生动物的任何发育问题。为了做到这一点,我们将在新生小型猪身上使用新的静脉制剂埃塞那肽进行毒理学研究。我们将始终关爱研究动物,尽量减少可能经历的痛苦、折磨、痛苦或持久的伤害。完成拟议的研究将使我们为临床试验做好准备。总而言之,这是一个令人兴奋的机会,可以为全世界受这种毁灭性疾病影响的婴儿提供一些真正的好处。潜在的好处可能会超过任何预期的安全担忧。埃克塞那肽有可能增强降温治疗的脑保护效果,并成为低收入国家的一线治疗药物,因为在这些国家,降温治疗不是一种选择。
英文摘要
Hypoxic-ischemic encephalopathy (HIE) occurs when a baby experiences reduced blood flow and oxygen delivery to the brain near the time of birth. When the amount of blood and oxygen supplied to the brain is reduced, the baby may sometimes sustain injury to the brain. Not all newborn babies exposed to this condition suffer brain injury. However, if brain injury occurs, there is high risk for death or neurologic disabilities including cerebral palsy, learning difficulties, epilepsy, and visual impairment. HIE is a global problem resulting in 400,000 babies with devastating neurodevelopmental impairment every year accounting for 2.4% of the total Global Burden of Disease.This Group have previously successfully developed therapeutic hypothermia (cooling) as treatment for HIE. Cooling the baby's body temperature for 3 days reduces the risk of brain injury after HIE. However, cooling therapy only helps about 1 in 7 infants with HIE. Therefore, additional treatments are needed to further improve brain function and brain recovery after HIE. Furthermore, it has been shown in clinical trials that cooling is not effective in low- and middle-income countries. We now propose that exenatide will reduce the incidence of cerebral palsy in babies born with HIE when combined with cooling treatment. Exenatide is a licensed anti-diabetic medicine which is now available as a generic drug. It is known to act on receptors present in the brain to protect it from further injury. In Parkinson's disease, results from animal studies and early human studies were encouraging leading to a large phase III clinical trial that is currently ongoing. We have investigated the potential brain protective effects of exenatide using rodent models of neonatal HIE. We know that if exenatide is administered as four injections 12-hours apart, in rodents who have experienced reduced blood flow and oxygen delivery to the brain, there is a significant reduction in brain injury. We also know that we can wait up to 6-hours after injury before starting treatment which is helpful for babies who need to travel to another hospital to receive treatment. In this proposal, we want to repeat the experiments in a higher animal model (piglets). We will first confirm the optimum dose of exenatide needed for brain protection in piglets. We will then randomise piglets who have been exposed to lack of blood and oxygen supply to either receive or not receive exenatide and find out if there are differences between the groups in their brains. Exenatide is currently commercially available as pens which allow for subcutaneous injections in adults. When medicines are given subcutaneously in babies their absorption can be slow and erratic. Since we want to reliably achieve high concentrations of exenatide rapidly in the body, we want to administer exenatide as an intravenous infusion. To do this and to make sure the medicine is safe for newborn babies, we aim to develop a new intravenous formulation of exenatide. Exenatide has proven safe in high dose animal studies and in human over-dose case reports. However, since we are administering exenatide to babies for the first time, we want to make sure it doesn't cause any developmental problems in newborn animals. To do this, we will conduct toxicology studies using the new intravenous formulation of exenatide in newborn minipigs. We will always care for the research animals, minimise the pain, suffering, distress or lasting harm that may be experienced. Completing the proposed research will bring us to readiness for clinical trials. In summary, this is an exciting opportunity to provide some real benefit to babies affected by this devastating condition throughout the world. The potential benefits are likely to outweigh any anticipated safety concerns. Exenatide has the potential to enhance the brain protective effects of cooling treatment and be a first line treatment in low-income countries where cooling treatment is not an option.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
SIRT1介导Exenatide改善糖尿病肾病的分子机制
  • 批准号:
    81670762
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2016
  • 负责人:
    蔡梦茵
  • 依托单位:
脊髓胰高血糖素样肽-1(GLP-1)受体镇痛作用及其信号通路
  • 批准号:
    81202517
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    23.0万元
  • 批准年份:
    2012
  • 负责人:
    马爱妞
  • 依托单位:
GLP-1受体特异性正电子显像剂18F-FBEM-cys40-exenatide的研制及在胰岛素瘤显像中的应用研究
  • 批准号:
    81101077
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    23.0万元
  • 批准年份:
    2011
  • 负责人:
    徐宇平
  • 依托单位:
骨髓干细胞移植联合Exendin-4治疗对移植胰岛新生血管形成及移植胰岛存活的影响
  • 批准号:
    30972908
  • 项目类别:
    面上项目
  • 资助金额:
    29.0万元
  • 批准年份:
    2009
  • 负责人:
    刘宝林
  • 依托单位: